In this episode, Drs. Ahmad Masri and Kevin Alexander review emerging clinical data in transthyretin amyloid cardiomyopathy (ATTR-CM) presented at the Heart Failure Society of America Annual Scientific Meeting and the American Heart Association Scientific Sessions 2025, including key findings from the ATTRibute-CM and HELIOS-B trials. The discussion highlights recent publications evaluating currently available disease-modifying therapies. Drs. Masri and Alexander translate these new data into practical insights for clinicians, focusing on how evolving evidence may influence treatment selection, therapeutic sequencing, and integration of disease-modifying therapies into everyday clinical practice.

Related References:

1. Huttin O, Sheikh FH, Brito D, et al. Efficacy of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy by baseline health status and quality of life. Presented at: Heart Failure Society of America Annual Scientific Meeting 2025; September 26–29, 2025; Minneapolis, MN.
2. Masri A, Judge DP, Ruberg FL, et al. Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CM. J Am Coll Cardiol. 2026;87(5):490-501. doi:10.1016/j.jacc.2025.09.013
3. Maurer MS, Alexander KM, Obici L, et al. Acoramidis lowers NT-proBNP in a larger proportion of ATTRibute-CM study participants with transthyretin amyloid cardiomyopathy compared with placebo, independent of atrial fibrillation status. Presented at: American Heart Association Scientific Sessions 2025; November 7–10, 2025; New Orleans, LA.
4. Stern LK, Ambardekar A, Grodin JL, et al. Acoramidis reduces all-cause mortality and cardiovascular-related hospitalizations through month 42 in transthyretin amyloid cardiomyopathy across all pre-specified participant subgroups. Presented at: American Heart Association Scientific Sessions 2025; November 7–10, 2025; New Orleans, LA.
5. Witteles R, Kristen A, Habib G, et al. Outcomes of the HELIOS-B monotherapy population: a post hoc analysis censoring data following tafamidis initiation. Presented at: Heart Failure Society of America Annual Scientific Meeting; September 26–29, 2025; Minneapolis, MN.